Core Viewpoint - The company plans to establish a specialized industry fund for brain-computer interfaces and brain science, with a total scale of 200 million yuan, to accelerate its strategic layout in this field [1] Group 1: Fund Details - The fund will be co-invested with professional investment institutions, with the company contributing 190 million yuan, accounting for 95% of the total committed capital [1] - The initial investment amount from the company is set at 50 million yuan, with the remaining contributions to be made based on project investment needs [1] Group 2: Investment Focus - The fund will target unlisted companies in the domestic and international brain-computer interface and brain science industry chain [1] - The aim is to enhance the company's industrial layout in brain-computer interfaces and neuroscience, promoting resource sharing and integration [1] Group 3: Strategic Goals - The fund seeks to achieve capital appreciation while serving the company's long-term strategic development goals [1] - The establishment of the fund is still pending approval from relevant authorities, and there are uncertainties regarding the smooth progress of investment projects [1]

Core Viewpoint - Botao Bio has received funding from the National Natural Science Foundation for a significant project focused on high-precision vascular interventional brain-machine interfaces, with direct funding amounting to 22 million yuan [1] Group 1 - The project titled "Research on Stent-free High-precision Vascular Interventional Brain-Machine Interfaces" is part of a major initiative under the National Natural Science Foundation [1] - Qingstone Yongjun is the only enterprise involved in this project, highlighting its unique position in the industry [1]

Market Overview - The Hong Kong stock market indices collectively rose on January 23, with the Hang Seng Index increasing by 0.45% to 26,749 points, the Hang Seng China Enterprises Index up by 0.51%, and the Hang Seng Tech Index rising by 0.62% [1][2]. Key Stock Movements - Major tech stocks saw gains, with Xiaomi Group and Kuaishou both rising nearly 3%, Alibaba up over 2%, and JD.com and Meituan also showing increases [2][4]. - The commercial aerospace sector experienced significant gains, with JunDa shares soaring over 51% following the launch of six platforms related to commercial aerospace in Beijing [6]. - Brain-computer interface stocks were active, with Lens Technology rising over 9% [7]. - Gold stocks continued to strengthen, with Zijin Mining International increasing by over 8% as gold prices reached new highs [9]. - Solar energy stocks surged, with Keyuan New Energy rising over 14% and several others following suit [10]. Sector Performance - The commercial aerospace sector led the market with notable gains, driven by the launch of new platforms aimed at enhancing the industry [6]. - The brain-computer interface sector showed strong activity, supported by advancements in flexible chip technology [7]. - Gold stocks benefited from rising gold prices, which reached a historical high of $4,940.78 per ounce [9]. - The solar energy sector was buoyed by positive remarks from Tesla's CEO regarding solar capacity expansion [10]. Individual Stock Highlights - JunDa shares rose by 51.40% to 39.00, while other aerospace-related stocks also saw significant increases [6]. - Lens Technology increased by 9.36% to 31.78, reflecting strong interest in brain-computer interface technologies [8]. - Zijin Mining International rose by 8.43% to 205.80, benefiting from the surge in gold prices [9]. - Keyuan New Energy saw a rise of 14.44% to 4.36, reflecting optimism in the solar energy market [11]. Future Outlook - The Hong Kong stock market is expected to see a recovery in profit growth by mid-2026, with a slowdown in competition among internet platforms and a reduction in the drag from non-essential consumer spending [26].

Core Viewpoint - The company,影石创新, is currently not involved in brain-computer interface technology but has developed a customized solution for a patient with ALS using their product, Link 2, in conjunction with third-party technology [1] Group 1: Company Technology and Products - The company provides a customized computer client called "Link Controller" that allows users to control the Link 2 camera through third-party brain-computer interfaces like Neuralink [1] - The Link 2 camera serves as a second pair of eyes for users, enabling them to see their surroundings through a camera feed displayed on a computer [1] - The company aims to leverage technology to help individuals experience life more fully and plans to continue focusing on the development, production, and sales of panoramic and action cameras [1]

21世纪经济报道记者周慧 北京报道 1月23日，国务院新闻办公室举行新闻发布会，介绍2025年知识产权工作进展情况。 国家知识产权局副局长芮文彪介绍，2025年共授权发明专利97.2万件，实用新型专利146.1万件，外观设计专利66.6万件。截至2025年底，国内（不含港澳 台）发明专利有效量达到532万件，每万人口高价值发明专利拥有量达到16件。专利密集型产业增加值占GDP比重升至2024年的13.38%，超额完成知识产 权"十四五"规划预期目标。 芮文彪提到，重点区域创新活跃。截至2025年底，长三角地区、京津冀地区和广东省的发明专利有效量分别为173.4万件、91.6万件和89.9万件，合计约占国 内总量的2/3；有效注册商标量合计2805.8万件，占国内总量的一半以上。在世界知识产权组织发布的2025年全球百强创新集群排名中，深圳—香港—广 州、北京、上海—苏州集群分别位居全球第1、第4和第6位。这些区域充分发挥了创新高地的作用，成为中国迈向知识产权强国的战略支点。 图：发布会现场 拍摄：周慧 在创新质量持续提升方面，芮文彪提到，中国国内（不含港澳台）有效发明专利中，高价值发明专利同比增速比总体水平高 ...

Group 1: Market Overview - The structural characteristics of the A-share market in 2026 are becoming increasingly distinct, with changes in sector rotation and investment logic shifting from broad allocation to selective stock picking [1] - Key investment opportunities in 2026 include left-side positioning in the pharmaceutical and cyclical sectors, exploration of new tracks in renewable energy and technology, and the realization of AI applications in media [1] Group 2: Pharmaceutical Sector - The pharmaceutical sector is expected to experience a mild rebound, with upcoming 2025 annual reports and 2026 Q1 reports serving as critical windows to validate the industry's recovery pace [2] - Focus areas include contract research organizations (CROs) and medical devices, particularly those with strong technological attributes and competitive R&D expense ratios [2] - The brain-computer interface field is highlighted as a promising area for future growth, with potential applications expected to emerge as market sentiment stabilizes [2] Group 3: Cyclical Sector - The cyclical industry is likely to show significant differentiation, with opportunities in precious metals and high-quality chemicals [3] - Precious metals, particularly silver, are expected to gain investment value if the gold bull market continues, while small metals related to AI and renewable energy may also present opportunities [3] - The chemical sector is currently at a bottoming phase, with expectations for price recovery, and stock selection should focus on industries with favorable competitive dynamics and new growth points [3] Group 4: Renewable Energy Sector - The lithium battery sector is anticipated to wait for quarterly report catalysts, while space photovoltaic and grid export sectors may open new growth avenues [5] - Space photovoltaic has significant market potential, with domestic companies expected to capture market share due to China's competitive advantage in the global photovoltaic industry [6] - The grid export sector is entering a performance realization phase, particularly for companies targeting the North American market, with expectations for order volume to increase this year [6] Group 5: AI and Media Sector - 2026 is expected to be a pivotal year for the realization of AI applications, with the media sector poised to benefit significantly [7] - Key focus areas include AI in marketing and multi-modal content generation, with the potential for substantial market growth in the video content sector [7][8] - The media sector's AI application market is expected to experience continuous upward movement, driven by competition among major internet companies and advancements in multi-modal technology [8] Group 6: Technology Sector - The AI industry is projected to evolve over the next 3-5 years, with a shift towards commercializing AI applications [9] - The robotics sector should focus on companies achieving performance milestones and those with potential to penetrate core supply chains [9]

Core Viewpoint - The medical ETF (159828) has seen a rise of over 1.3% on January 23, with net inflows exceeding 100 million yuan for five consecutive days, indicating market interest in clinical value and innovation in the healthcare sector [1]. Group 1: Investment Focus - Future investments in the pharmaceutical sector should emphasize the intrinsic logic of clinical value, which addresses the clinical needs of patients and healthcare providers, with both domestic and international policies assigning higher premiums to clinical value [1]. - The pharmaceutical and biotechnology sectors are driven by innovation (including overseas expansion, AI, and new technologies), performance validation, policy benefits, and seasonal market movements, with a short-term focus on innovative drugs and CXO [1]. Group 2: Key Themes and Directions - High-elasticity sub-themes include AI in healthcare/pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs, which are expected to gain traction [1]. - Continuous attention is required on the collaboration outcomes from the JPM conference, clinical data for innovative drugs, and performance realization [1]. - In the realm of innovative medical devices, there is optimism regarding the upgrade of high-end medical equipment and high-value consumables [1]. Group 3: ETF and Index Information - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the A-share market involved in medical devices, medical services, and medical information technology to reflect the overall performance of related listed companies in China's healthcare industry [1].

Core Insights - The article emphasizes the significant influence of Elon Musk on the capital market, particularly through his various ventures, which are seen as investment opportunities. Group 1: Investment Themes - The article identifies five main concepts associated with Elon Musk: electric vehicles (primarily Tesla), robotics (Optimus humanoid robot), commercial space (SpaceX), brain-machine interfaces (Neuralink), and artificial intelligence (xAI) [1][2]. - Tesla's Full Self-Driving (FSD) version 14.2 has achieved "zero takeover" capability across the U.S., and the Austin Robotaxi is currently in testing [1]. - SpaceX is preparing for an IPO with Starlink, which has over 10 million global users and a target valuation of $1.5 trillion [2]. Group 2: Commercial Space Developments - SpaceX plans to launch a second-generation Starlink satellite communication system in 2027, which will enhance capacity by over 100 times and increase data throughput by more than 20 times [3]. - Competitor Blue Origin, led by Jeff Bezos, announced plans to deploy over 5,400 satellites to create a new communication network [3]. - In China, Blue Arrow Aerospace is preparing for an IPO and aims to develop a fully reusable commercial crewed spacecraft, with plans to reduce ticket prices significantly [4]. Group 3: Market Sentiment and Volatility - The commercial space and robotics sectors are characterized as non-profitable and highly volatile, where market movements are driven more by news and developments than by financial performance [4]. - Recent announcements in the commercial space sector have led to a strong rebound in the market, indicating the importance of positive news flow in these industries [4].

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

Core Insights - The fourth quarter of 2025 saw significant adjustments in the portfolio of renowned fund manager Fu Pengbo, with notable changes in top holdings and investment strategies [1][4]. Group 1: Portfolio Adjustments - In the fourth quarter of 2025, Maiwei Co. replaced China Mobile in Fu Pengbo's top ten holdings, indicating a shift in focus towards high-performing sectors [1]. - Fu Pengbo increased holdings in Cambricon Technologies while reducing positions in several companies including Xinyi Semiconductor, Shenghong Technology, CATL, Tencent Holdings, Dongshan Precision, Luxshare Precision, Alibaba-W, and Juxing Technology [1][3]. Group 2: Market Conditions and Economic Outlook - The central economic work conference and political bureau meeting emphasized maintaining low social financing costs and leaving room for fiscal policy to address future risks, reflecting a cautious yet optimistic outlook for domestic demand policies [1][4]. - The macroeconomic data for the fourth quarter indicated a mixed performance in consumption and investment, with automotive consumption boosted by trade-in subsidies, while real estate remained weak [4]. Group 3: Investment Strategy and Future Outlook - The concentration of the top ten holdings in the fund increased to 70.38%, up from 66.04% in the previous quarter, indicating a strategic focus on fewer, high-potential stocks [5]. - Preparations for the 2026 portfolio include reducing exposure to companies with weak fundamentals and increasing investments in data center cooling, storage, and computing power-related firms, based on industry trends and individual stock research [5]. - The market is expected to see heightened activity in early 2026, with a focus on sectors like AI, non-ferrous metals, and lithium battery materials anticipated to show significant growth [6].